PainReform (NASDAQ:PRFX) Trading Down 2.1% – Here’s What Happened

PainReform Ltd. (NASDAQ:PRFX)’s stock price fell 2.1% on Tuesday . The company traded as low as $0.9003 and last traded at $0.9330. 60,892 shares were traded during trading, a decline of 53% from the average session volume of 130,229 shares. The stock had previously closed at $0.9532.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Wall Street Zen upgraded PainReform from a “strong sell” rating to a “hold” rating in a report on Friday, October 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, PainReform currently has an average rating of “Sell”.

PainReform Price Performance

The company has a 50 day simple moving average of $1.11 and a 200-day simple moving average of $1.40. The stock has a market capitalization of $1.88 million, a P/E ratio of -0.01 and a beta of 0.56.

PainReform (NASDAQ:PRFX) last announced its quarterly earnings data on Wednesday, October 1st. The company reported ($0.55) earnings per share for the quarter.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.